Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival.

ABSTRACT:

Background and objectives

We examined the association between the disease-modifying drugs (DMDs) for multiple sclerosis (MS) and survival in a multiregion population-based study.

Methods

We accessed multiple administrative health databases from 4 Canadian provinces. Persons with MS were identified and followed from the most recent of the first MS or demyelinating event or January 1, 1996 (index date), until death, emigration, or December 31, 2017. Association between the first-generation and second-generation DMDs and all-cause mortality was examined using stratified Cox proportional hazard models, reported as adjusted hazard ratios (aHRs). Timing of DMD initiation was explored, with findings reported at 2, 5, or 10 years postindex date, representing very early, early, or la

SUBMITTER: Ng HS 

PROVIDER: S-EPMC9210547 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature